ESSEN
DÜSSELDORF
COLOGNE

CLINIC MEETS BIOLOGY

# WEST GERMAN LYMPHOMA SYMPOSIUM

## PROGRAMME

24th and 25th May 2024

Conference Center Essen | Germany

Hybrid Event

# CONTACT

**Scientific lead and response for the programme**

**Universitätsmedizin Essen**

Department of Haematology and Stem Cell Transplantation
West German Cancer Center
University Hospital Essen (AöR)
Hufelandstraße 55, 45147 Essen (Germany)

Unter der Schirmherrschaft der
DGHO
DEUTSCHE GESELLSCHAFT FÜR HÄMATOLOGIE UND MEDIZINISCHE ONKOLOGIE

In co-operation with

CANTAR

CRC | SFB 1530 Elucidation and targeting of pathogenic mechanisms in B cell malignancies

**Meeting Office / Organizer and Contact**
CSi Hamburg GmbH
Goernestraße 30, 20249 Hamburg (Germany)
+49 40 307 703 00
meetings@csihamburg.de
contact on site
+49 157 35730006

CSI HAMBURG CONFERENCES SYMPOSIA INCENTIVES

**Venue**
Conference Center Essen
Huyssenallee 53
45128 Essen (Germany)
Nordrhein-Westfalen (NRW)

**Hybrid Event**
To follow the live stream with Q&A
www.lymphoma-symposium.de/stream
password: Lym-Sym24
(instructions will be shown)

**Media library**
Contributions - video on demand
available from
Monday, 27th May 2024
12:00 (CET)

SCAN ME

# WELCOME

**Dear Colleagues and Guests**

The field of preclinical and clinical lymphoma research has seen a dramatic acceleration of progress during the last years, ranging from a molecular characterization of the disease to the development of novel mouse models, as well as preclinical drug development, ultimately culminating in massive advances in our current treatment algorithms, now involving CAR-T cells, various novel (bispecific) antibodies and new small molecule compounds.

In parallel to these scientific developments, within the state of Northrhine-Westphalia, the large comprehensive cancer centers CIO-ABCD (Aachen, Bonn, Cologne, Düsseldorf) and WTZ-EM (Essen, Münster) have strategically strengthened their collaboration, particularly through the establishment of the National Cancer Center West NCT-West (Essen, Cologne), and have further consolidated and expanded their clinical and translational lymphoma programs.

Given these developments, we are excited to launch the West German Lymphoma Symposium, to facilitate the scientific exchange within the region, excite young researchers for lymphoma research, and, most importantly, to further expand our international visibility and outreach.

The organizing team of the West German Lymphoma Symposium is happy to be part of our inaugural meeting.

A warm welcome to Essen,
with all our best wishes
Conference chair 2024

**Christian Reinhardt, Prof. Dr**
University Hospital Essen, West German Cancer Center

**Bastian v. Tresckow, Prof. Dr**
University Hospital Essen, West German Cancer Center

**Ralf Küppers, Prof. Dr**
University Hospital Essen, Institute for Cell Biology (tumour research)

**Peter Borchmann, Prof. Dr**
University Hospital Cologne, Clinic for Internal Medicine
Oncology/ Haematology

**Sascha Dietrich, Prof. Dr**
University Hospital Düsseldorf
Clinic for Haematology, Oncology and Clinical Immunology

from 09:30 Registration

10:45 Welcome
Scientific committee

**11:00 - 1:00** **SESSION 1**
**The germinal center reaction as a catalyst for lymphoma development**
**Chair** Christian Reinhardt, University Hospital Essen (GER)

**11:00** **Role of Super-enhancer Hypermutation in the Pathogenesis of Diffuse Large B cell Lymphoma**
Riccardo Dalla-Favera, Columbia University New York (USA)

**11:25** **Genetics-driven epigenetic disruption of the germinal center program in B cell lymphomas**
Laura Pasqualucci, Columbia University New York (USA)

**11:50** **Aspects of Hodgkin lymphoma biology**
Ralf Küppers, University Hospital Essen (GER)

**12:15** **Modelling Sporadic Oncogenic Events in Lympho magenesis**
Dinis Calado, The Francis Crick Institute London (UK)

**12:40** **Short talk I**
*»Unveiling Follicular Lymphoma's Common Progenitor Cells«*
Oscar Atkins, The Francis Crick Institute (UK)

**12:50** **Discussion**

**1:00 - 2:00** **Break**

Day 1 | Friday, 24th May 2024

**2:00 - 4:00** **SESSION 2**
**Epigenetic rewiring as a driver and target of lymphomagenesis**
**Chair** Peter Borchmann, University Hospital Cologne (GER)

**2:00** **Mechanisms and therapeutic targeting of the malignant immune system**
Ari M. Melnick, Weill Cornell Medicine New York (USA)

**2:25** **Development of small molecules for epigenetic targets**
Stefan Knapp, Goethe-University Frankfurt (GER)

**2:50** **Harnessing state switches in aggressive B-cell lymphoma**
Clemens Schmitt, Charité - University Hospital Berlin (GER)

**3:15** **DNA-methylation based classification of lymphomas: A tool to come?**
Reiner Siebert, Ulm University Hospital (GER)

**3:40** Remote **Toward the noninvasive characterization of lymphomas and their microenvironments**
Ash A. Alizadeh, Stanford University / Stanford Comprehensive Cancer Center (USA)

**4:00 - 6:00** **POSTER PRESENTATION AND GET-TOGETHER**

The poster presentation is divided into 2 poster walks. Per poster: introduction/ presentation 6 minutes + 6 minutes discussion. The best poster presentation of each group will be honoured with a poster prize, during the closing ceremony.

**GROUP 1** **PO-01 to PO-09**
Chairs: Ralf Küppers, University Hospital Essen (GER);
Bastian von Tresckow, University Hospital Essen (GER)

**PO-01**

**Common Origins and Somatic Mutation Patterns of Composite Lymphomas - Two Models of Lymphomagenesis**

**V. Berg**[1], B. Budeus[1], K. Danielzik[2], M. Dampmann[1, 3], S. Dolff[4], S. Esser[5], D. Hoffmann[2], R. Küppers[1]
[1] University Hospital Essen, Institute of Cell Biology, Essen, North Rhine-Westphalia, Germany
[2] University of Duisburg-Essen, Bioinformatics and Computational Biophysics, Essen, Germany
[3] University Hospital Essen, Department of Hematology, Essen, Germany
[4] University Hospital Essen, Department of Infectious Diseases, Essen, Germany
[5] University Hospital Essen, Department of Dermatology and Venerology, Essen, Germany

**PO-02**

**B Cell Differentiation in the Germinal Centre Reaction**

**A.-K. Schnormeier**[1], B. Budeus[1], B. Höing[3], M. A. Weniger[1], D. Hoffmann[2], R. Küppers[1]
[1] University Duisburg-Essen, Institute of Cell Biology (Tumour Research), Essen, North Rhine-Westphalia, Germany
[2] University Duisburg-Essen, Bioinformatics and Computational Biophysics, Essen, North Rhine-Westphalia, Germany
[3] University Medical Centre Essen, Otolaryngology, Essen, North Rhine-Westphalia, Germany

**PO-03**

**DSMZCellDive: a web tool for browsing and analyzing transcriptomic data of hematological cell lines**

S. Nagel[1], C. Pommerenke[1], J. Koblitz[2], L. Steenpaß[1], **S. Eberth**[1]
[1] Leibniz-Institute, Department of Human and Animal Cell Lines, Braunschweig, Saxony, Germany
[2] Leibniz-Institute, Department of Bioinformatics and Databases, Braunschweig, Saxony, Germany

Day 1 | Friday, 24th May 2024

**PO-04**

**Distinct chemokine receptor expression profiles in the development and early progression of follicular lymphoma**

**A. Zupo**[1], K. Pansy[1], L. Gaksch[1], J. Waldhart[3], A. Brunner[3], M. Szmyra-Polomka[1], S. Haingartner[1], J. Haybaeck[3, 5], C. Beham-Schmid[6], P. V. Tomazic[7], H. Greinix[1], P. Neumeister[1], B. Uhl[1], J. Feichtinger[8], K. T. Prochazka[1], A. Deutsch[1]
[1] Medical University of Graz, Division of Hematology, Graz, Steiermark, Austria
[2] Medical University of Graz, Diagnostic & Research Center for Molecular BioMedicine, Institute of Pathology, Graz, Austria
[3] University Medical Centre Maribor, Department of Pathology, Maribor, Slovenia
[4] Medical University of Graz, Institute of Pathology, Graz, Austria
[5] Medical University of Graz, Department of Otorhinolaryngology, Graz, Austria
[6] Medical University of Graz, Division of Cell Biology, Histology and Embryology, Graz, Austria

**PO-05**

**Functional vs. Genomic-based Precision Medicine in Hematological Cancers: Feasibility Analysis of the EXALT-2 Study**

**L. Kazianka**[1], T. Pemovska[1], J. Rohrbeck[2], C. Kornauth[2], A. Pichler[1], C. Agreiter[1], S. Lubowitzki[1], K. Prochazka[3], P. Neumeister[3], C. Schmitt[4], R. Greil[5], W. Willenbacher[6], D. Wolf[6], U. Jäger[1], I. Simonitsch-Klupp[2], P. Staber[1]
[1] Medical University of Vienna, Department of Medicine I, Division of Hematology, Vienna, Austria
[2] Medical University of Vienna, Department of Pathology, Vienna, Austria
[3] Medical University of Graz, Department of Hematology, Graz, Austria
[4] Kepler Universitätsklinikum Linz, Division of Hematology, Linz, Austria
[5] Paracelsus Medical University Salzburg, Department of Medicine III, Salzburg, Austria
[6] Medical University of Innsbruck, Department of Medicine V, Innsbruck, Austria

**PO-06**

**Deep learning-based classification of diffuse large B-cell lymphoma cell-of-origin by gene expression profiles**

R. Kumar[1], **K. Kundal**[1], A. Viswanathan[2], A. Sengupta[1], A. Kumar[1], K. V. Kumar[1]
[1] Indian Institute of Technology Hyderabad, Biotechnology, Sangareddy, India
[2] Amrita Vishwa Vidyapeetham, School of Biotechnology, Amritapuri, India

**WITHDRAWN**

**PO-07**

**LUBAC activity is required for ABC-DLBCL pathogenesis**

**D. Bonasera**[1, 2], J. Saggau[1, 2], J. Valiulis[3], J. Löber[4], M. Peifer[3], C. Rheinhardt[5], B. Chapuy[4], A. Montinaro[7], G. Liccardi[2, 6], H. Walczak[1, 7]
[1] University of Cologne, Cell death, inflammation and immunity laboratory, Institute of Biochemistry I, Centre for Biochemistry, Faculty of Medicine, Cologne, North Rhine-Westphalia, Germany
[2] University of Cologne, Genome instability, inflammation and cell death laboratory, Institute of Biochemistry I, Centre for Biochemistry, Faculty of Medicine, Cologne, North Rhine-Westphalia, Germany
[3] University of Cologne, Department of Translational Genomics, Cologne, North Rhine-Westphalia, Germany
[4] Charité, Department of Hematology, Oncology and Tumorimmunology, Berlin, Brandenburg, Germany
[5] Univeristy Hospital Essen, Department of Hematology and Stem Cell Transplantation, Essen, North Rhine- Westphalia, Germany
[6] University of Cologne, Center for Molecular Medicine Cologne (CMMC), Cologne, North Rhine-Westphalia, Germany
[7] University College London, Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, London, United Kingdom

**PO-08**

**A rationale for dual PIM and PI3K inhibition in peripheral T-cell lymphoma**

**M. Lohrberg**[1], M. Heber[1], N. Ksionko[1], N. Schmidt[1], R. Koch[1]
[1] University Medical Center Göttingen, Haematology and medical Oncology, Göttingen, Lower Saxony, Germany

**PO-09**

**Senolytic capacity of obinutuzumab in t(14;18)-positive GCB DLBCL**

**M. Stegemann**[1], X. Sun[2], M. Schönlein[3], D. Belenki[4, 2], G. Kandler[2], M. Hummel[5], S. Lee[6], A. Bittner[2], S. Denker[2], F. Benthani[1], P. Richter-Pechanska[2], Y. Yu[1], C. A. Schmitt[1,2]
[1] Kepler University Hospital, Johannes Kepler University, Department of Hematology and Oncology, Linz, Austria
[2] Charité - University Medical Center, Virchow Campus, and Molekulares Krebs-forschungszentrum, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany
[3] University Medical Center Hamburg-Eppendorf, Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, Hamburg, Germany
[4] Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
[5] Charité - Universitätsmedizin, Department of Pathology, Berlin, Germany
[6] Johannes Kepler University, Institute of Tumor Biology, Linz, Austria

shared first authorship with Xinxin Sun



Day 1 | Friday, 24th May 2024

**GROUP 2** **PO-10 to PO-18**
Chairs: Peter Borchmann, University Hospital Cologne (GER); Sascha Dietrich, University Hospital Düsseldorf (GER)

**PO-10**

**Identification of ferroptosis sensitizers for DLBCL treatment**

**J. Labisch**[1], G. Lenz[1], A. Schmitt[1], S. Hailfinger[1]
[1] University Hospital Münster, Münster, North Rhine-Westphalia, Germany

**PO-11**

**In vitro secretome analysis of primary CLL cells and genetically modified B cells**

**L. Osswald**[1, 2], P. Giansanti[3], F. Bassermann[1, 2], M. Schmidt-Supprian[1, 2]
[1] Technial University of Munich, Department of Medicine III, Hematology and Oncology, Munich, Bavaria, Germany
[2] Technical University of Munich, Institute of Experimental Hematology, Center for Translational Cancer Research(TranslaTUM), Munich, Bavaria, Germany
[3] Technical University of Munich, Core Facility of Proteomics and Bioanalytics, Bavarian Center for Biomolecular Mass Spectrometry at the University hospital Rechts der Isar (BayBioMS@MRI), Center for Translational Cancer Research (TranslaTUM), Munich, Bavaria, Germany

**PO-12**

**Modulation of tumour microenvironment by BIRC3-loss-of-function in CLL**

**S. Lyu**[1], A. Rudersdorff[1], Ö. Veli[1], D. Mocanu[1], R. Brinker[1], M. Michalik[1], S. Blakermore[1], C. Pallasch[1], N. Peltzer[1]
[1] University of Cologne, CECAD Excellence Center, Köln, North Rhine-Westphalia, Germany

**PO-13**

**Brusatol synergizes with venetoclax to induce cell death in aggressive lymphomas both in vitro and ex vivo.**

**M. M. Szmyra-Połomka**[1], S. Haingartner[1], K. Pansy[1], P. Kovács-Hajdu[2], V. Boškova[2], N. Krall[2], P. V. Tomazic[3], B. Uhl[1], H. T. Greinix[1], P. Neumeister[1], C. Beham-Schmid[4], G. Höfler[4], F. R. Vagena[4], E. M. Bernhart[5], M. A. Dengler[6], B. Klösch[7], A. J.A. Deutsch[1]
[1] Medical University of Graz, Division of Clinical Haematology, Department of Internal Medicine, Graz, Steiermark, Austria
[2] Exscientia, Vienna, Wien, Austria
[3] Medical University of Graz, Department of General Otorhinolaryngology, Head and Neck Surgery, Graz, Steiermark, Austria
[4] Medical University of Graz, Diagnostic and Research Institute of Pathology, Graz, Steiermark, Austria
[5] Medical University of Graz, Division of Molecular Biology and Biochemistry, Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Graz, Steiermark, Austria
[6] Medical University of Graz, Division of Oncology, Department of Internal Medicine, Graz, Steiermark, Austria
[7] Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Graz, Steiermark, Austria

**PO-14**

### Detection of occurrent somatic hypermutation and associated gene expression profile in single follicular lymphoma B cells

J. H. Sepúlveda Yáñez[1, 2], D. Alvarez Saravia[3], D. Medina[3], E. Quinten[1], S. Kloet[4], P. M. Jansen[5], S. M. Kiełbasa[6], M. A. Navarrete[2], C. A.M. van Bergen[1], **H. Veelken**[1]

[1] Leiden University Medical Center, Hematology, Leiden, Netherlands
[2] Universidad de Magallanes, School of Medicine, Punta Arenas, Chile
[3] Universidad de Magallanes, Centro Asistencial Docente e Investigación, Punta Arenas, Chile
[4] Leiden University Medical Center, Human Genetics, Leiden, Netherlands
[5] Leiden University Medical Center, Pathology, Leiden, Netherlands
[6] Leiden University Medical Center, Biomedical Data Sciences, Leiden, Germany

**PO-15**

### Molecular analysis of B-cell dysfunction in patients with chronic lymphocytic leukemia (CLL)

**M. Dampmann**[1, 2], B. Budeus[2], M. Elbert[2], J. von Tresckow[1], H. C. Reinhardt[1], M. Seifert[4], R. Küppers[2]

[1] University Hospital Essen, Department of Hematology and Stem Cell Transplantation, Essen, North Rhine-Westphalia, Germany
[2] University Duisburg-Essen, Institute for Cell Biology (Cancer Research), Essen, North Rhine-Westphalia, Germany
[3] University Hospital Düsseldorf, Department of Hematology, Oncology and Clinical Immunology, Düsseldorf, North Rhine-Westphalia, Germany

**PO-16**

### Understanding the role of cFLIP in the pathogenesis of Diffuse Large B Cell Lymphoma

**K. T. Bariboloka**[1, 2], D. P. Savcigil[1, 2], G. Gangarossa[4], K. Nugraha[3], C. C. Fraile[1], A. Annibaldi[1, 2]

[1] University Hospital Cologne, Center for Molecular Medicine Cologne, Cologne, North Rhine-Westphalia, Germany
[2] University of Cologne, Cologne, North Rhine-Westphalia, Germany
[3] University of Lausanne, Department of Immunology, Lausanne, Vaud, Switzerland
[4] University of Florence, Department of Experimental and Clinical Biomedical Sciences, Florence, Italy

Day 1 | Friday, 24th May 2024

**PO-17**

### Machine-learning based body composition analysis in patients receiving CD19-directed CAR-T cell therapy

**F. Ullrich**[1], S. Flossdorf[2], R. Hosch[3], F. Nensa[3, 4], F. Barbato[5], M. Teichert[1], H. C. Reinhardt[1], E. Kocakavuk[1, 3], N. R. Neuendorff[6, 1], B. von Tresckow[1]

[1] University Hospital Essen, Department of Hematology and Stem Cell Transplantation, Essen, Germany
[2] University Hospital Essen, Institute for Medical Informatics, Biometry and Epidemiology, Essen, Germany
[3] University Hospital Essen, Institute for Artificial Intelligence in Medicine, Essen, Germany
[4] University Hospital Essen, Institut for Diagnostic and Interventional Radiology and Neuroradiology, Essen, Germany
[5] University Hospital Essen, Department of Nuclear Medicine, Essen, Germany
[6] Ruhr University Bochum, Marien Hospital Herne, Department of Geriatrics, Herne, Germany

**PO-18**

### An In Vivo PiggyBac Insertional Mutagenesis Screen Reveals Oncogenic Lesions Cooperating With Myd88L265P

**S. Höfmann**[1], R. Flümann[2, 3], J. Hansen[2, 5], S. Klein[1], J. Meinel[7], P. Pfeiffer[2], H. Goldfarb-Wittkopf[2, 5], A. Lütz[2, 5], J. Wirtz[2, 5], M. Möllmann[1], T. Zhou[1], A. Tabatabai[1], T. Lohmann[2], F. Beleggia[2, 4], B. W. Pelzer[6], F. Ullrich[1], A. Arora[1], T. Persigehl[8], R. Büttner[7], B. v. Tresckow[1], R. D. Jachimowicz[2, 3], G. Knittel[1], H.C. Reinhardt[1]

[1] University Hospital Essen, Dept. of Hematology and Stem Cell Transplantation, West German Cancer Center, German Cancer Consortium Partner Site Essen, Center for Molecular Biotechnology, Essen, Germany
[2] University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany
[3] University of Cologne, Center for Molecular Medicine, Cologne, Germany
[4] Mildred Scheel School of Oncology Aachen Bonn Cologne Düsseldorf (MSSO ABCD), Faculty of Medicine and University Hospital of Cologne, Cologne, Germany
[5] Max Planck Institute for Biology of Ageing, Cologne, Germany
[6] Cornell University, Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, New York, United States of America
[7] University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Cologne, Germany
[8] University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Radiology and Interventional Radiology, Cologne, Germany

**8:00 - 10:00** **SESSION 3**
**Genetic rewiring encodes actionable vulnerabilities in lymphoma**
**Chair** Sascha Dietrich, University Hospital Düsseldorf (GER)

**8:00** **Genetic bases of immune evasion in lymphoma**
Margaret Shipp, Dana Farber/Harvard Cancer Center Boston (USA)

**8:25** **Curing aggressive lymphomas with aggressive combinations of targeted agents**
Louis Staudt, National Cancer Institute Bethesda (USA)

**8:50** **Actionable Alterations in LBCL**
Björn Chapuy, Charité University Medicine Berlin (GER)

**9:15** **Elucidation of Lymphoma Proteogenotypes**
Thomas Oellerich, University Hospital Frankfurt (GER)

**9:40** **Short talk II**
*»Autonomous B-cell receptor signaling in activated B-cell DLBCL: A lymphomagenic driver with functional equivalence to an activating CARD11 variant«*
Hendrik Veelken, Leiden University Medical Center (NL)

**9:50** **Discussion**

**10:00 - 10:30** **Break**

**10:30 - 12:30** **SESSION 4**
**The next frontier: harnessing the immune system for lymphoma therapy**
**Chair** Bastian von Tresckow, University Hospital Essen (GER)

**10:30** **Chemotherapy free approaches in first line LBCL - a dream or a reality?**
Jason Westin, University of Texas MD Anderson Cancer Center Houston (USA)

**10:55** **Enhancing immunotherapies for germinal center-derived B cell lymphomas by EZH2 inhibition**
Wendy Béguelin, Weill Cornell Medicine New York, (USA)

**11:20** **Multi-omic profiling of CaR T cell treated aggressive B-cell lymphoma reveals a CSF1R+ myeloid-monocytic cell compartment mediating CaR T cell resistance**
Roland Ullrich, University Hospital Cologne (GER)

**11:45** **Bispecific T Cell Engagers in Follicular Lymphoma: Promises and Path ahead**
Elisabeth Budde, City of Hope National Medical Center Duarte (USA)

**12:10** **Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities**
Sascha Dietrich, University Hospital Düsseldorf (GER)

**12:35** **Discussion**

**12:45 - 1:45** **Break**

**1:45 - 3:30** **SESSION 5**
**Mechanisms of resistance and definition of high-risk DLBCL**

**Chair** Ralf Küppers, University Hospital Essen (GER)

**1:45** **Short talk III**
*»Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas«*
S. Scheich, University Hospital Frankfurt, Frankfurt (GER)

**1:55** **Mechanisms of resistance and definition of high-risk DLBCL**
Andrew Davies, Southampton General Hospital (UK)

**2:20** **Overcoming therapy resistance through single-cell functional precision medicine approaches**
Philipp Staber, Medical University of Vienna (AUT)

**2:45** **Autochthonous mouse models of DLBCL enable in vivo genetic screening and serve as a platorm for preclinical validation of actionable vulnerabilities**
Christian Reinhardt, University Hospital Essen (GER)

**3:10** **Discussion**

**3:30** **Closing remarks**
and Poster presentation award

Farewell and Goodbye







## ALIZADEH ASH A., MD, PHD

Professor of Medicine
Stanford University | Stanford Comprehensive Cancer Center
Stanford, USA

## BÉGUELIN WENDY, PHD.

Assistant Professor of Pharmacology in Medicine
Weill Cornell Medicine
New York, USA



## BUDDE ELIZABETH LIHUA, MD, PHD

Associate Professor
Dept. of Hematology & Hematopoietic Cell Transplantation
Executive Medical Director,
Enterprise Immune Effector Cell Program
City of Hope National Medical Center, Duarte California
Duarte, USA

## BORCHMANN PETER, PROF. DR

University Hospital Cologne Clinic for Internal Medicine
Oncology | Haematology
Cologne, GER

Faculty | Speakers, in alphabetical order



## CALADO DINIS, PHD

Principal Investigator
London Research Institute
The Francis Crick Institute
London, UK

## CHAPUY BJÖRN, PROF. DR

Charité University Medicine Berlin
Berlin, GER

## DALLA-FAVERA RICCARDO, MD

Professor
Director, Institute for
Cancer Genetics
Columbia University
New York, USA

## DAVIES ANDREW, PROF. DR

Professor of Haematological Oncology and Honorary Consultant
Chair National Cancer Research Institute Lymphoma Research Group
Director Southampton NCRI | CR UK Experimental Cancer Medicines Centre
Southampton General Hospital
Southhampton, UK

## DIETRICH SASCHA, PROF. DR

Director of the Clinic for Haematology, Oncology and Clinical Immunology
University Hospital
Düsseldorf, GER

## KNAPP STEFAN, PROF. DR

Professor of Pharmaceutical Chemistry
CSO Structural Genomics Consortium, Frankfurt
Institute of Pharmaceutical Chemistry
Goethe-University Frankfurt
Frankfurt am Main, GER

## KÜPPERS RALF, PROF. DR RER. NAT.

Deputy Managing Director
Institute for Cell Biology (tumour research)
University Hospital Essen
Essen, GER

## MELNICK ARI M., MD

Gebroe Professor of Hematology and Medical Oncology
Joan and Sanford Weill Department of Medicine
Professor of Immunology and Pharmacology
Weill Cornell Medicine
New York, USA

Faculty | Speakers, in alphabetical order

## OELLERICH THOMAS, PROF. DR

Director Department of Hematology and Oncology,
University Hospital Frankfurt
Frankfurt am Main, GER

## PASQUALUCCI LAURA, MD

Professor of Pathology and Cell Biology
Institute for Cancer Genetics Columbia University
New York, USA

## REINHARDT CHRISTIAN, PROF. DR

Director Department of Haematology and Stem Cell Transplantation
West German Cancer Center
University Hospital Essen
Essen, GER

## SCHMITT CLEMENS, PROF. DR

Johannes Kepler University
Kepler University Hospital, Med. Dep. of Hematology, Oncology
Linz, AT
Max-Delbrück-Center for Molecular Medicine, and Charité
University Hospital, Campus Virchow-Clinic,
Molecular Cancer Research Center
Berlin, GER



## SHIPP MARGARET, MD

Chief, Division of Hematologic Neoplasia, Dana Farber Cancer Institute
Director, DFCI Lymphoma Research Center
Professor, Harvard Medical School
Boston, USA

## SIEBERT REINER, PROF. DR

Professor of Human Genetics
Director, Institute of Human Genetics
Ulm University Hospital
Ulm, GER

## STABER PHILIPP, PROF. DR

Clinical Director, Lymphoid Malignancies and Precision Hematology;
Department of Medicine I
Division of Hematology & Hemostaseology
Medical University of Vienna
Vienna, AUT

## STAUDT LOUIS M., MD., PH.D.

Director, Center for Cancer Genomics
Chief, Lymphoid Malignancies Branch National Cancer Institute
Bethesda, USA

Faculty | Speakers, in alphabetical order

## ULLRICH ROLAND, UNIV.-PROF. DR. MED. DR. NAT. MED.

University Hospital Cologne
Clinic for Internal Medicine
Cologne, GER



## VON TRESCKOW BASTIAN, PROF. DR

Deputy Director Department of Haematology and Stem Cell Transplantation
West German Cancer Center
University Hospital Essen
Essen, GER

## WESTIN JASON, MD, MS, FACP

Professor
Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
Department of Lymphoma & Myeloma
University of Texas MD Anderson Cancer Center
Houston, USA

## Sponsors and Exhibitors

MAIN SPONSORS

abbvie

Lilly

Roche

THANK YOU ALL VERY MUCH

Bristol Myers Squibb™

Incyte

BeiGene

Janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson&Johnson

MSD

sobi

Takeda

In accordance with the recommendations of the German Medical Association, the Association of Scientific Medical Societies and the Voluntary Self-Regulation of the Pharmaceutical Industry (FSA Code of Conduct for Healthcare Professionals, Section 20 (5)), the contributions (net amounts, before deduction of costs) of the industry partnerships are disclosed. The above-mentioned companies are participating in the West German Lymphoma Symposium in return for services.
Net amounts, before deduction of costs. AbbVie Deutschland GmbH & Co. KG, 50,000 € - BeiGene, 5.000 € - Bristol-Myers Squibb GmbH & Co. KGaA, 20,000 € - Incyte Inc., 10,000 € - Janssen-Cilag GmbH, 5.000 € - Lilly Deutschland GmbH, 50,000 € - MSD Sharp & Dohme GmbH, 5.000 € - Roche Pharma AG, 50.000 € - sobi GmbH, 5.000 € - Takeda Pharma Vertrieb GmbH & Co. KG, 5,000 € - Status: 05/2024

www.lymphoma-symposium.de